| 2008-12-04: |
Results From the First and Largest Collaborative Study Confirm Role of Enbrel( R ) in Psoriatic Arthritis
Maidenhead, England ( PRN/ots ) - - New Data Add to the Body of Evidence That Show That Enbrel ( Etanercept ) Clears Skin and Can Sustain This Efficacy Over Time New data presented today at the 'Gene to Clinic' meeting taking place at the Royal (...) |
| 2008-12-04: |
European Commission Approval of New Indication for Roche's Pegasys( R ) ( peginterferon alfa - 2a ) Offers Hepatitis C Patients a Second Chance for a Cure
Basel ( PRN/ots ) - - Pegasys is the First and Only Pegylated Interferon to be Approved for Treatment of up to 72 Weeks in Treatment - Experienced Patients Roche announced today that the European Commission has approved Pegasys( R ) ( peginterferon alfa - 2a ( 0 KD ) ) plus Copegus( R ) (...) |
| 2008-12-03: |
Wyeth Submits European Marketing Authorization Application for its 13 - Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
Collegeville, Pennsylvania ( PRN/ots ) - - Approval sought for investigational vaccine for protection against the 13 most prevalent serotypes associated with serious pneumococcal disease Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today that it has submitted a marketing authorization application ( MAA ) to the (...) |
| 2008-12-03: |
PREZISTA( R ) ( darunavir ) Receives Expanded Marketing Authorisation in the European Union for Treatment - Experienced Adults With HIV - 1
Cork, Ireland ( PRN/ots ) - - For Medical Media Only - PREZISTA now Indicated for the Broad Range of Treatment - Experienced Patients in the 27 EU Member States Tibotec Pharmaceuticals announced today that the European Commission adopted the decision to broaden the indication for PREZISTA( R ) (...) |
| 2008-11-27: |
European Committee for Human Medicinal Products ( CHMP ) Issues Positive Opinion for Once - Daily PREZISTA( R ) ( Darunavir ) as Part of Combination Therapy for Treatment - Naïve Adults With HIV - 1
Cork, Ireland, November 27 ( PRN/ots ) - The Committee for Human Medicinal Products ( CHMP ) has issued a positive opinion recommending approval for once - daily dosing of 800 mg PREZISTA( R ) ( darunavir ) with low - dose ritonavir as part of combination therapy in treatment - naïve adults ( those who (...) |
| 2008-11-27: |
Bacardi Limited Offers "Driving Experience of a Lifetime" With F1( TM ) Legend Michael Schumacher
Hamilton, Bermuda, November 27 ( PRN/ots ) - - Schumacher - The Ultimate Designated Driver - Promotes Drinking and Driving Don't Mix at http://www.championsdrinkresponsibly.com Bacardi Limited, as part of its responsible drinking "Champions Drink Responsibly" campaign, is providing the drive of a lifetime - the opportunity (...) |
| 2008-11-21: |
New Antibiotic Against Serious Infections
Beerse, Belgium, November 21 ( PRN/ots ) - - European Authority Recommends Approval of ZEVTERA( TM ) BEERSE, Belgium, November 21 /PRNewswire/ - - - A Broad - spectrum, Anti - MRSA Cephalosporin Antibiotic to Treat Complicated Skin and Soft Tissue Infections BEERSE, Belgium, November 21 /PRNewswire/ - - The Committee for (...) |
| 2008-11-21: |
Nplate( TM ) ( Romiplostim ) Receives Positive Opinion for Marketing Authorisation in the European Union
Thousand Oaks, California, November 21 ( PRN/ots ) - - First and Only Approved Platelet Producer Represents New Treatment Approach for Serious Chronic Autoimmune Disorder Amgen ( Nasdaq: AMGN ) today announced that the European Committee for Medicinal Products for Human Use ( CHMP ) has issued a (...) |
| 2008-11-21: |
CHMP Recommends Approval of New Indication for Enbrel( R ) as Treatment for Severe Psoriasis in Paediatric Patients
Maidenhead, England, November 21 ( PRN/ots ) - - Not for UK Journalists The European Committee for Medicinal Products for Human Use ( CHMP ) today announced its positive recommendation for the approval of Enbrel( R ) ( etanercept ) as a treatment for children aged 8 years and over and (...) |
| 2008-11-21: |
New Biologic Ustekinumab Receives Positive Opinion From European Regulatory Authority for the Treatment of Moderate to Severe Plaque Psoriasis
Beerse, Belgium, November 21 ( PRN/ots ) - Janssen - Cilag announced today that ustekinumab, the first in a new class of biologics, has received a positive opinion for the treatment of moderate to severe plaque psoriasis from the European Committee for Medical Products for Human Use (...) |
| 2008-11-20: |
Intel Announces its First Home Medical Device in the United Kingdom to Better Connect Clinicians With Patients
London, November 20 ( PRN/ots ) - - Intel( R ) Health Guide is the First Product in a Series Designed to Enable More Personalised Care Management for Chronic and Age - related Conditions Intel Corporation today announced the Intel( R ) Health Guide, a care management tool designed for (...) |
| 2008-11-20: |
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
Cork, Ireland, November 20 ( PRN/ots ) - - Nearly 90 Percent of Patients Achieve Undetectable Viral Load in Phase IIa Trial Within 28 Days of Combined Treatment With Standard of Care New clinical data demonstrate the safety and antiviral activity of TMC435, an investigational (...) |
| 2008-11-20: |
Tibotec Begins Enrollment in Europe for Phase III Trial of Telaprevir in HCV Patients who Failed Prior Treatment
Cork, Ireland, November 20 ( PRN/ots ) - - Telaprevir Data Presented at AASLD Tibotec BVBA today announced that it has begun enrolling patients in its phase III study of telaprevir ( VX - 950 ), an investigational protease inhibitor ( PI ), in patients with chronic genotype 1 hepatitis (...) |
| 2008-11-17: |
Quest Diagnostics' Laboratory in India Accredited by Two Leading Laboratory Accrediting Organizations
Madison, New Jersey and Gurgaon, India, November 17 ( PRN/ots ) - - Less than one tenth of one percent of labs in India are CAP and NABL accredited - Quest Diagnostics' laboratory also becomes one of only five labs in India to achieve NGSP (...) |
| 2008-11-17: |
First Pivotal Trials Begin for Boehringer Ingelheim's Novel Triple Angiokinase Inhibitor Vargatef( TM ) ( BIBF 1120 )
Ingelheim, Germany, November 17 ( PRN/ots ) - - Progress Continues Across Expanding Oncology Pipeline With Two Compounds now in Phase III Clinical Development and a Potential First - in - Class Polo - Like Kinase 1 Inhibitor Soon to Enter Phase II - For non - US Healthcare (...) |
| 2008-11-14: |
SYGNIS Receives Orphan Drug Designation from the European Commission for AX200 in the treatment of Spinal Cord Injury
Heidelberg ( na Originaltextservice ) - - Second indication for AX200 given Orphan Drug status SYGNIS Pharma AG ( Frankfurt: LIO; ISIN DE0005043509; Prime Standard ), today announced that it has received Orphan Drug designation from the European Commission for AX200 in the treatment of Spinal (...) |
| 2008-11-13: |
Avastin( R ) Gives an Additional 4 Months of Life to Patients With one of the Most Common Types of Lung Cancer
Basel, Switzerland, November 13 ( PRN/ots ) - - Phase III Trial Shows Patients With Advanced Adenocarcinoma of the Lung Have a 45 Prozent Better Chance of Survival With Avastin Roche announced today that an exploratory analysis of the pivotal phase III E4599 study demonstrated (...) |
| 2008-11-13: |
New Antibiotic Against Serious Infections - Receives First Approval in Europe
Baar, Switzerland, November 13 ( PRN/ots ) - - ZEVTERA( TM ) A Broad - spectrum, Anti - MRSA Cephalosporin Antibiotic to Treat Complicated Skin and Soft Tissue Infections Approved in Switzerland - Not for UK Media Swissmedic, the Swiss agency for therapeutic products, has approved ZEVTERA( TM ) ( ceftobiprole medocaril ) for (...) |
| 2008-11-12: |
Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants
Paris, November 12 ( PRN/ots ) - - Sanofi Pasteur and Chumakov Institute Russian Academy Medical Sciences Providers of Inactivated Polio Vaccine ( IPV ) IMOVAX PolioTM for Russia National "Project Health" Sanofi Pasteur, the vaccines division of sanofi - aventis Group, announced today that Russia has chosen (...) |
| 2008-11-12: |
Tibotec Data Presented at ICAAC and HIV9 Follow key Regulatory Approvals for Anti - HIV Compounds
Glasgow, Scotland, November 12 ( PRN/ots ) - - Not Intended for Journalists in the UK or Ireland - New Findings From ARTEMIS and TITAN Studies Demonstrate Growth of the Tibotec Virology Franchise New data on PREZISTA( R ) ( darunavir ), a protease inhibitor from Tibotec, will be (...) |
| 2008-11-11: |
Dronedarone ( Multaq( R ) ) Reduced the Incidence and Duration of Hospitalization in Patients With Atrial Fibrillation
New Orleans, Louisiana, November 11 ( PRN/ots ) - - New Post - Hoc Analysis From Athena Study Showed That Multaq( R ) on Top of Standard Therapy Significantly Decreased the Total Number of Hospital Days by 28 Prozent in Patients With Atrial Fibrillation or Flutter NEW ORLEANS, Louisiana, November (...) |
| 2008-11-11: |
DAIICHI SANKYO and Arqule enter Into Strategic R&D Partnership to Progress Novel Compounds to Target Cancer
Munich ( na Originaltextservice ) - Product development agreement focused on ARQ 197, c - Met inhibitor, with discovery collaboration directed toward novel kinase inhibitors ArQule, Inc. ( NASDAQ: ARQL ) and DAIICHI SANKYO Co., Ltd. ( TSE: 4568 ) today announced that they have entered into (...) |
| 2008-11-10: |
RVX - 208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease
Calgary, Canada, November 10 ( PRN/ots ) - - First in Class Drug Illustrates Early Signal of Transport of Key Amyloid Marker From Brain - TSX Exchange Symbol: RVX Resverlogix Corp. ( "Resverlogix" ) ( TSX:RVX ) announced today that treatment with its lead drug RVX - 208, a (...) |
| 2008-11-10: |
First Study in Real - Life Setting Confirms That Once - Monthly Mircera Keeps Haemoglobin Levels Within a Tight Range
Basel, Switzerland, November 10 ( PRN/ots ) - - Results Demonstrate Effective and Simplified Approach to Anaemia Management in Chronic Kidney Disease Patients on Dialysis Interim study results from 90 renal centres in Germany confirm for the first time that in a real - life (...) |
| 2008-11-10: |
Unique New Initiative by World - Recognized Specialists in Heart Disease and Diabetes to Reduce Residual Vascular Risk Launched Today
New Orleans and Los Angeles, November 10 ( PRN/ots ) - - Current Treatment Fails to Abolish Majority of Vascular Risk - Residual Risk Reduction Initiative ( R3i ) Calls for Action to Reduce the Lipid - Related Residual Vascular Risk Unaddressed by Current Standards of Care in (...) |
| 2008-11-09: |
CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
New Orleans, November 9 ( PRN/ots ) - New data from the JUPITER study demonstrated that CRESTOR( R ) ( rosuvastatin calcium ) 20 mg significantly reduced major cardiovascular ( CV ) events ( defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death (...) |
| 2008-11-07: |
Atrial Fibrillation Found to be Common in Patients With Atherothrombosis, Increases Risk of Cardiovascular Death, Heart Attack and Stroke
Tokyo, November 7 ( PRN/ots ) - - Large, International REACH Registry Also Shows Many Patients With Atrial Fibrillation are Undertreated With Antiplatelet and Anticoagulant Therapies A significant portion of patients with atherothrombosis also have atrial fibrillation ( AF ), greatly increasing their risk for cardiovascular death, heart (...) |
| 2008-11-07: |
Media Alert From Residual Risk Reduction Initiative ( R3i ): 19:00 CST Sunday 9 November 2008
New Orleans, Louisiana, November 7 ( PRN/ots ) - - Residual Vascular Risk Reduction: The Global Call to Action - Announcement of the Launch of the Residual Risk Reduction Initiative: R3i KEY FACTS: Residual Risk Reduction Initiative ( R3i ) calls for action to reduce the (...) |
| 2008-11-05: |
Personalising Cancer Care - An Invitation
Ingelheim, Germany, November 5 ( PRN/ots ) - - For Non - US Healthcare Media Can the quest for personalised medicine in cancer therapy ever be realised? And how far have we come in the journey to personalised cancer care? What lies ahead from (...) |
| 2008-11-01: |
New Study Shows That Pegasys Regimen Provides Higher Cure Rates for Hepatitis C Patients
Basel, Switzerland, November 1 ( PRN/ots ) - A new, independently - conducted study being presented at AASLD shows that PEGASYS( R ) ( peginterferon alfa - 2a ( 40KD ) ) regimens result in higher cure rates for hepatitis C patients compared to regimens with another pegylated interferon.( 1 ) Comparing Today's Standard Treatment Regimens: (...) |
| 2008-10-31: |
Largest Study of its Kind Reveals Low Sexual Desire is Most Common Female Sexual Problem
Ingelheim, Germany ( PRN/ots ) - - 1 in 10 Women Experience Distress Associated With the Most Common Form of Female Sexual Dysfunction, yet the Condition Remains Largely Under - Recognised and Under - Diagnosed - For non - US media only Results from the PRESIDE*( 1 ) survey, (...) |
| 2008-10-28: |
Therapure Biopharma Inc. Announces Collaboration With Induce Biologics Inc.
Toronto, Canada ( PRN/ots ) - - Ontario Biotech Companies Work Together on Innovative Bone Protein Technology TORONTO, Canada, October 28 /PRNewswire/ - - Thomas Wellner, President and CEO of Therapure BioPharma Inc. and Dr. Cameron Clokie, President and CEO of Induce Biologics Inc. today announced a (...) |
| 2008-10-27: |
Phase 3 Data Indicate Investigational 13 - valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two
Washington ( PRN/ots ) - - Data presented at the joint annual meeting of ICAAC and IDSA - Results suggest candidate vaccine may be as effective as Prevnar for the seven shared serotypes, and provide expanded coverage for six additional serotypes - Wyeth on track to (...) |
| 2008-10-27: |
New Study Shows ENBREL( R ) ( etanercept ) Is More Effective than a DMARD in the Treatment of Symptoms of Ankylosing Spondylitis Patients
Maidenhead, England ( PRN/ots ) - - Data From Another Study Supported the use of ENBREL for up to Five Years in Ankylosing Spondylitis Patients New safety and efficacy data for active ankylosing spondylitis ( AS ) patients treated with ENBREL( R ) ( etanercept ) were presented at the American (...) |
| 2008-10-24: |
GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology
Paris ( PRN/ots ) - - GenOdyssee Has Received Notice of Allowance of European Patent Application Covering Its Core Natural Evolution Technology Invented in 2002, and Received Broad Product Applications Protection Rights to All Cytokine Families GenOdyssee ( GO ), a biotechnology company dedicated to the discovery and (...) |
| 2008-10-23: |
Sanofi - aventis is Complying With the EMEA's Recommendation to Temporarily Suspend the Marketing Authorisation of Acomplia( R ) in Obese and Overweight Patients
Paris ( PRN/ots ) - - Sanofi - aventis Will Comply With the European Authorities Request to Temporarily Suspend the Marketing Authorisation of Acomplia( R ) in Obese and Overweight Patients and Will Make Every Effort to Actively Support Patients and Health Care Professionals in This Process. - Sanofi - aventis (...) |
| 2008-10-22: |
Boehringer Ingelheim Broadens Oncology Pipeline With Promising New Data for Potentially First in Class Plk1 Inhibitor
Ingelheim, Germany ( PRN/ots ) - - BI 6727, a Highly Potent and Selective Plk1 inhibitor, Represents Latest Advance in Company's Plk1 Programme - For non - US Healthcare Media Boehringer Ingelheim's most promising new cell cycle kinase inhibitor and potentially first - in - class compound, BI (...) |
| 2008-10-17: |
From Curiosity to Discovery: Boehringer Ingelheim's Pipeline Update Unveils Novel Investigational Compounds Heralding the Company's Entry Into Type 2 Diabetes
Ingelheim and Biberach, Germany ( PRN/ots ) - - Boehringer Ingelheim Oncology Pipeline Advances: Two Leading Compounds are Entering Phase III Trials - Boehringer Ingelheim's Investigational Compound in Development for the Treatment of Pre - Menopausal Women Suffering From Hypoactive Sexual Desire Disorder ( HSDD ) Will Report on (...) |
| 2008-10-15: |
Wyeth Provides Regulatory Update Regarding Desvenlafaxine for the Treatment of Major Depressive Disorder
Collegeville, Pennsylvania ( PRN/ots ) - - Company Underscores Commitment to Availability in Worldwide Markets Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), today provided an update on its global strategy for desvenlafaxine for the treatment of major depressive disorder ( MDD ) in adults. Desvenlafaxine has (...) |
| 2008-10-12: |
Europeans Face a Painful Truth on First Ever Neuropathic Pain Day - October 13
London ( PRN/ots ) - - Not for UK Journalists - New Survey Reveals Widespread Ignorance of Debilitating Pain Condition Affecting Millions of Europeans Alarmingly, nearly sixty per cent of Europeans have never heard of neuropathic pain ( NeP ), ( 1 ) a debilitating nerve condition that affects approximately (...) |
| 2008-10-07: |
Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
KVISTGÅRD, Denmark, October 7 ( PRN/ots ) - - 125 Patient, Prospective Randomized Placebo - Controlled Phase II Study Shows Statistically Significant Improved Overall Survival KVISTGÅRD, Denmark, October 7 /PRNewswire/ - - Bavarian Nordic has now evaluated the mature phase II data from the therapeutic prostate cancer (...) |
| 2008-10-06: |
Botaneco Receives Natural Ingredient Approval From ECOCERT( R ) for Hydresia( TM ) G2
Calgary, Canada ( PRN/ots ) - - Hydresia( TM ) G2 Approved by leading European Authority on Natural Organic Certification TSX symbol: SBS Botaneco Specialty Ingredients Inc. ( Botaneco ), a subsidiary of SemBioSys Genetics Inc. ( SemBioSys ), today announced that its second generation oleosome product, Hydresia( TM ) G2, has been (...) |
| 2008-10-02: |
UNICEF and Pampers Announce Partnership Aimed at Eliminating Deadly Disease by 2012
Geneva ( PRN/ots ) - - Actress, Producer and Mother Salma Hayek Calls for Participation in Campaign to Eliminate Disease Responsible for the Death of one Newborn Baby Approximately Every Three Minutes A global review confirms that the elimination of maternal and newborn tetanus, preventable (...) |
| 2008-10-02: |
Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
Stockholm ( PRN/ots ) - Athera Biotechnologies AB and Dyax Corp. ( NASDAQ:DYAX ) announced today that they have entered into a collaboration to discover and to develop therapeutic products for the prevention or treatment of cardiovascular inflammatory diseases. The collaboration follows the recent publication of work (...) |
| 2008-10-02: |
Driving Change in Mental Health Through Science and Community
Beerse, Belgium ( PRN/ots ) - Today, Janssen - Cilag are celebrating their 50 year commitment to researching and developing innovative medicines to help improve the lives of people with mental health problems. Back in 1958, the late Dr. Paul Janssen developed one of the first anti - (...) |
| 2008-09-26: |
Kelly Osbourne and International Health Groups Call for Improved Education on Choices and Usage of Contraception
London ( PRN/ots ) - - World Contraception Day 2008 Highlights Scale and Impact of Unplanned Pregnancy Today, international sexual and reproductive health experts and successful recording artist and media personality Kelly Osbourne, call for more action to address the burgeoning problem of unplanned pregnancies and (...) |
| 2008-09-25: |
Recent Research Shows Significant Benefits in Acute Ischaemic Stroke With Actilyse( R ) Beyond Currently Approved Three Hour Treatment Window
Ingelheim, Germany ( PRN/ots ) - - For Healthcare Media Outside the U.S.A., Canada, and Japan - Favourable Safety and Efficacy Profile of Actilyse( R ) Confirmed by ECASS 3 Study Investigating Treatment in an Extended Time Window up to 4.5 Hours After Symptom Onset First results (...) |
| 2008-09-24: |
Landmark UPLIFT Study Reaffirms the Safety of Spiriva ( tiotropium ) in Patients With Chronic Obstructive Pulmonary Disease
Leuven, Belgium ( PRN/ots ) - - For Media Outside US and Canada - Prof. dr. Marc Decramer, Head of Pneumology of the University Hospitals Leuven, is Lead Investigator of the International UPLIFT Study Investigating Treatment of COPD Patients With tiotropium. Today he Elaborates on the (...) |
| 2008-09-23: |
Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins
Collegeville, Pennsylvania ( PRN/ots ) - - 85,000 Expected to Enroll in Phase 4 Study Initiated Pre - Registration - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), today announced the initiation of the Community Acquired Pneumonia Immunization Trial in Adults a major study in adults (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
